SCHEMBL21151024

SCHEMBL21151024

CC(C)c1cc2c(C(C)(C)C)cccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 8/20 0.49
DHFR P00374 1/20 0.39
SLC2A1 P11166 1/20 0.39
CA2 P00918 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
ALDH1A1 P00352 3/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CCNB2 O95067 1/20 0.31
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
CCNB3 Q8WWL7 1/20 0.31
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
AHR P35869 1/20 0.31
CHRNB2 P17787 1/20 0.30
CHRNA7 P36544 1/20 0.30
CHRNA4 P43681 1/20 0.30
VDR P11473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21212192 0.85 KIF11 (0.47) KIF11DHFRSLC2A1ALDH1A1HPGD
SCHEMBL19286546 0.77 KIF11 (0.53) KIF11CA2GABRA1GABRB2ALDH1A1
SCHEMBL24974318 0.77 KIF11 (0.53) KIF11CA2GABRA1GABRB2ALDH1A1
SCHEMBL24371171 0.77 DHFR (0.42) KIF11DHFRSLC2A1CA2GABRA1
SCHEMBL19737437 0.77 DAO (0.50) KIF11DHFRSLC2A1ALDH1A1HPGD
SCHEMBL25574661 0.75 KIF11 (0.51) KIF11CA2GABRA1GABRB2ALDH1A1
SCHEMBL16380970 0.75 DAO (0.49) KIF11DHFRSLC2A1ALDH1A1HPGD
SCHEMBL24447564 0.75 RHEB (0.42) KIF11DHFRSLC2A1ALDH1A1HPGD
SCHEMBL16380895 0.75 DHFR (0.48) KIF11DHFRSLC2A1ALDH1A1HPGD
SCHEMBL16380899 0.75 DAO (0.49) KIF11DHFRSLC2A1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B KIF11 3592/4885DHFR 3003/4885SLC2A1 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.